These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31201052)

  • 21. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
    Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
    Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
    Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
    García-Díaz A; López-Andújar P; Rodríguez Díaz J; Montava R; Torres Barceló C; Ribes JM; Buesa J
    Vaccine; 2004 Dec; 23(4):489-98. PubMed ID: 15530697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive protection to bovine rotavirus (BRV) infection induced by a BRV VP8* produced in plants using a TMV-based vector.
    Pérez Filgueira DM; Mozgovoj M; Wigdorovitz A; Dus Santos MJ; Parreño V; Trono K; Fernandez FM; Carrillo C; Babiuk LA; Morris TJ; Borca MV
    Arch Virol; 2004 Dec; 149(12):2337-48. PubMed ID: 15338319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
    Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
    PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody.
    Ward RL; McNeal MM; Sheridan JF
    Virology; 1992 May; 188(1):57-66. PubMed ID: 1314467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.
    Kanai Y; Onishi M; Kawagishi T; Pannacha P; Nurdin JA; Nouda R; Yamasaki M; Lusiany T; Khamrin P; Okitsu S; Hayakawa S; Ebina H; Ushijima H; Kobayashi T
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33087468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VP6: A candidate rotavirus vaccine.
    Ward RL; McNeal MM
    J Infect Dis; 2010 Sep; 202 Suppl():S101-7. PubMed ID: 20684688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a Bacillus subtilis-based rotavirus vaccine.
    Lee S; Belitsky BR; Brinker JP; Kerstein KO; Brown DW; Clements JD; Keusch GT; Tzipori S; Sonenshein AL; Herrmann JE
    Clin Vaccine Immunol; 2010 Nov; 17(11):1647-55. PubMed ID: 20810679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence and phylogenetic analyses of human rotavirus strains: comparison of VP7 and VP8(∗) antigenic epitopes between Tunisian and vaccine strains before national rotavirus vaccine introduction.
    Mouna BH; Hamida-Rebaï MB; Heylen E; Zeller M; Moussa A; Kacem S; Van Ranst M; Matthijnssens J; Trabelsi A
    Infect Genet Evol; 2013 Aug; 18():132-44. PubMed ID: 23684631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.
    Feng N; Burns JW; Bracy L; Greenberg HB
    J Virol; 1994 Dec; 68(12):7766-73. PubMed ID: 7966566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.
    Wen X; Cao D; Jones RW; Li J; Szu S; Hoshino Y
    Vaccine; 2012 Sep; 30(43):6121-6. PubMed ID: 22885016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Recognition of Sialic Acid and αGal Epitopes by the VP8* Domains of the Bovine Rotavirus G6P[5] WC3 and of Its Mono-reassortant G4P[5] RotaTeq Vaccine Strains.
    Alfajaro MM; Kim JY; Barbé L; Cho EH; Park JG; Soliman M; Baek YB; Kang MI; Kim SH; Kim GJ; Park SI; Pendu JL; Cho KO
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
    Malm M; Heinimäki S; Vesikari T; Blazevic V
    Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice.
    Andrés I; Rodríguez-Díaz J; Buesa J; Zueco J
    Biotechnol Bioeng; 2006 Jan; 93(1):89-98. PubMed ID: 16193515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea.
    Ruggeri FM; Johansen K; Basile G; Kraehenbuhl JP; Svensson L
    J Virol; 1998 Apr; 72(4):2708-14. PubMed ID: 9525588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral immunization of mice with Lactococcus lactis expressing the rotavirus VP8* protein.
    Rodríguez-Díaz J; Montava R; Viana R; Buesa J; Pérez-Martínez G; Monedero V
    Biotechnol Lett; 2011 Jun; 33(6):1169-75. PubMed ID: 21302132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.